Effects of antidepressant on FKBP51 mRNA expression and neuroendocrine hormones in patients with panic disorder
Objective The purpose of this study was to investigate the effects of escitalopram on the peripheral expression of hypothalamic-pituitary-adrenal (HPA) axis-related genes (FKBP51, HSP90, NR3C1 and POMC) and HPA-axis hormones in patients with panic disorder (PD). Methods Seventy-seven patients with PD were treated with escitalopram for 12 weeks. All participants were assessed for the severity of panic symptoms using the Panic Disorder Severity Scale (PDSS). The expression of HPA-axis genes was measured using real-time quantitative fluorescent PCR, and ACTH and cortisol levels were measured using chemiluminescence at baseline and after 12 weeks of treatment. Results At baseline, patients with PD had elevated levels of ACTH and cortisol, and FKBP51 expression in comparison to healthy controls (all p < 0.01). Correlation analysis revealed that FKBP51 expression levels were significantly positively related to cortisol levels and the severity of PD (all p < 0.01). Furthermore, baseline ACTH and cortisol levels, and FKBP51 expression levels were significantly reduced after 12 weeks of treatment, and the change in the PDSS score from baseline to post-treatment was significantly and positively related to the change in cortisol (p < 0.01). Conclusions The results suggest that PD may be associated with elevated levels of ACTH and cortisol, and FKBP51 expression, and that all three biomarkers are substantially decreased in patients who have received escitalopram treatment..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
BMC psychiatry - 24(2024), 1 vom: 10. Apr. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zou, Zhili [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| BKL: | |
|---|---|
| Themen: |
| Anmerkungen: |
© The Author(s) 2024 |
|---|
| doi: |
10.1186/s12888-024-05704-4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR05548297X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR05548297X | ||
| 003 | DE-627 | ||
| 005 | 20240411064704.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240411s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12888-024-05704-4 |2 doi | |
| 035 | |a (DE-627)SPR05548297X | ||
| 035 | |a (SPR)s12888-024-05704-4-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.00 |2 bkl | ||
| 100 | 1 | |a Zou, Zhili |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effects of antidepressant on FKBP51 mRNA expression and neuroendocrine hormones in patients with panic disorder |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2024 | ||
| 520 | |a Objective The purpose of this study was to investigate the effects of escitalopram on the peripheral expression of hypothalamic-pituitary-adrenal (HPA) axis-related genes (FKBP51, HSP90, NR3C1 and POMC) and HPA-axis hormones in patients with panic disorder (PD). Methods Seventy-seven patients with PD were treated with escitalopram for 12 weeks. All participants were assessed for the severity of panic symptoms using the Panic Disorder Severity Scale (PDSS). The expression of HPA-axis genes was measured using real-time quantitative fluorescent PCR, and ACTH and cortisol levels were measured using chemiluminescence at baseline and after 12 weeks of treatment. Results At baseline, patients with PD had elevated levels of ACTH and cortisol, and FKBP51 expression in comparison to healthy controls (all p < 0.01). Correlation analysis revealed that FKBP51 expression levels were significantly positively related to cortisol levels and the severity of PD (all p < 0.01). Furthermore, baseline ACTH and cortisol levels, and FKBP51 expression levels were significantly reduced after 12 weeks of treatment, and the change in the PDSS score from baseline to post-treatment was significantly and positively related to the change in cortisol (p < 0.01). Conclusions The results suggest that PD may be associated with elevated levels of ACTH and cortisol, and FKBP51 expression, and that all three biomarkers are substantially decreased in patients who have received escitalopram treatment. | ||
| 650 | 4 | |a Panic disorder |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a HPA axis |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Neuroendocrine hormone |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Escitalopram |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Huang, Yulan |e verfasserin |4 aut | |
| 700 | 1 | |a Maes, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Jinyu |e verfasserin |4 aut | |
| 700 | 1 | |a He, Ying |e verfasserin |4 aut | |
| 700 | 1 | |a Min, Wenjiao |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Bo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMC psychiatry |d BioMed Central, 2001 |g 24(2024), 1 vom: 10. Apr. |w (DE-627)SPR027777154 |w (DE-600)2050438-X |x 1471-244X |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2024 |g number:1 |g day:10 |g month:04 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s12888-024-05704-4 |m X:VERLAG |x 0 |z kostenfrei |3 Volltext |
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.00 |q VZ |
| 951 | |a AR | ||
| 952 | |d 24 |j 2024 |e 1 |b 10 |c 04 | ||